Provided by Tiger Trade Technology Pte. Ltd.

AN2 Therapeutics, Inc.

1.04
-0.0500-4.59%
Post-market: 1.040.00000.00%16:10 EST
Volume:101.43K
Turnover:108.19K
Market Cap:28.50M
PE:-0.92
High:1.09
Open:1.06
Low:1.03
Close:1.09
52wk High:1.55
52wk Low:1.00
Shares:27.40M
Float Shares:19.16M
Volume Ratio:1.09
T/O Rate:0.53%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.1292
EPS(LYR):-1.7206
ROE:-45.91%
ROA:-28.35%
PB:0.47
PE(LYR):-0.60

Loading ...

AN2 Therapeutics CEO to Join Fireside Chat at Leerink Global Healthcare Conference

Reuters
·
Feb 17

AN2 Therapeutics Inc. Files Initial Beneficial Ownership Statement for Principal Accounting Officer Sarah Joanne Williams

Reuters
·
Feb 04

AN2 Therapeutics Appoints Sarah Williams as Vice President and Principal Accounting Officer

Reuters
·
Jan 30

AN2 Therapeutics announces FDA clearance of OSHU IND application

TIPRANKS
·
Jan 12

FDA Clears AN2 Therapeutics Epetraborole Trial for M. abscessus Lung Disease

Reuters
·
Jan 12

AN2 Therapeutics Inc - Patient Enrollment for Trial Expected to Begin in Q1 2026

THOMSON REUTERS
·
Jan 12

AN2 Therapeutics Announces FDA Clearance to Proceed With 90-Patient Investigator-Initiated Trial (Iit) of Epetraborole in Patients With M. Abscessus Lung Disease

THOMSON REUTERS
·
Jan 12

AN2 Therapeutics Advances Chagas Disease and Oncology Programs and Reports Third Quarter 2025 Results

Reuters
·
Nov 13, 2025

AN2 Therapeutics Q3 net loss narrows to $9.4 mln

Reuters
·
Nov 13, 2025

Press Release: AN2 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business and Scientific Highlights

Dow Jones
·
Nov 13, 2025

REFILE-BUZZ-U.S. STOCKS ON THE MOVE-Guardant Health, Tower Semiconductor, GlobalFoundries

Reuters
·
Nov 11, 2025

BUZZ-U.S. STOCKS ON THE MOVE-Instacart, Plug Power, Crypto stocks

Reuters
·
Nov 10, 2025

AN2 Therapeutics, GSK Collaborate to Develop New Therapies for Tuberculosis

MT Newswires Live
·
Nov 10, 2025

Shares of AN2 Therapeutics up 1.8% After GSK Collaboration to Develop Tuberculosis Treatment

THOMSON REUTERS
·
Nov 10, 2025

BRIEF-AN2 Therapeutics Announces Research Collaboration With GSK

Reuters
·
Nov 10, 2025

AN2 Therapeutics Partners with GSK to Develop Boron-Based Tuberculosis Treatments

Reuters
·
Nov 10, 2025

AN2 Therapeutics Announces Research Collaboration With GSK to Advance Boron-Based Leurs-Inhibitors Targeting Tuberculosis (Tb)

THOMSON REUTERS
·
Nov 10, 2025

AN2 Therapeutics Inc. Officer Joshua M. Eizen Reports Disposal of Common Shares

Reuters
·
Nov 07, 2025

AN2 Therapeutics CEO to Join Fireside Chat at Evercore HealthCONx Conference

Reuters
·
Nov 07, 2025

AN2 Therapeutics Inc expected to post a loss of 22 cents a share - Earnings Preview

Reuters
·
Nov 01, 2025